Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patie...

Full description

Bibliographic Details
Main Authors: Kazuma Ohyashiki, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Kenko Azuma, Tetsuzo Tauchi, Seiichi Okabe, Yutaka Fukuoka, Junko H. Ohyashiki
Format: Article
Language:English
Published: MDPI AG 2016-04-01
Series:International Journal of Molecular Sciences
Subjects:
plasma miR-215
chronic myeloid leukemia
imatinib
discontinuation
Online Access:http://www.mdpi.com/1422-0067/17/4/570

Internet

http://www.mdpi.com/1422-0067/17/4/570

Similar Items